CSL EBIT

The latest EBIT for CSLLY is $8.2B as of June 2026. That compares with $6.6B in the prior-year period — up 25.1% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside CSL's historical trend and sector peers before judging valuation or financial health.

Over the past year, CSLLY's EBIT moved from $6.6B to $8.2B — a 25.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CSL's operating scale or balance-sheet position.

Against Healthcare companies, CSLLY currently prints $8.2B for EBIT, while the sector average sits near $22B. That is roughly 63.2% below the sector mean. Large gaps often invite a closer look at CSL's growth, margins, and balance sheet.

A EBIT figure of $8.2B for CSLLY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting CSLLY's EBIT ($8.2B), review year-over-year change from $6.6B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.